angiotensin receptor blockers (ARBs) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Nouri-Vaskeh IRCT20180802040678N4		RCT	angiotensin receptor blockers (ARBs)	calcium channel blocker	COVID 19 hospitalized	some concern	41/41	inconclusive	inconclusive 65 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Duarte NCT04355936		RCT	angiotensin receptor blockers (ARBs)	standard of care	COVID 19 hospitalized	high	41/41	suggested	suggested 1.2-fold increase in hospital discharge but with a low degree of certainty due to high risk of bias
COVID 19 all comers meta-analysis
University of Minnesota NCT04312009		RCT	losartan	placebo	COVID 19 all comers	some concern	101/104	inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis